Michael A Metzger sold $2.6M of SNDX
Chief Executive Officer at Syndax Pharmaceuticals Inc. 157,307 shares at an average of $16.41, traded Sep 8, 2025, filed Sep 8, 2025.
Score components
- +25RoleCEO
- +25Trade size$2.6M at market
- +10Share of holdings soldSold 34% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-113659, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 8, 2025 | MOption exercise Common Stock10b5-1 | +157,307 | $10.90 | $1.7M | 455,968 | Sep 8, 2025 |
| Sep 8, 2025 | SOpen-market sale Common Stock10b5-1 | -157,307 | $16.41 | $2.6M | 298,661 | Sep 8, 2025 |
| Sep 8, 2025 | MOption exercise Stock options (Right to buy)derivative10b5-1 | +157,307 | $0.00 | $0 | 0 | Sep 8, 2025 |
Related signals
Other insiders at Syndax Pharmaceuticals Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | Syndax Pharmaceuticals Inc | Dennis Podlesak director | $875k 57,600 shares | -27% | |
| 30Weak | Syndax Pharmaceuticals Inc | Keith A. Goldan Chief Financial Officer | $12k 1,296 shares | -1% | |
| 41Moderate | Syndax Pharmaceuticals Inc | Michael A Metzger Chief Executive Officer | $70k 7,534 shares | -2% | |
| 68Notable | Syndax Pharmaceuticals Inc | Nicholas A.J. Botwood Head of R&D, CMO | $106k 11,765 shares | +50% | |
| 57Moderate | Syndax Pharmaceuticals Inc | Martin H. Huber Jr. director | $45k 5,000 shares | +7% | |
| 60Notable | Syndax Pharmaceuticals Inc | Keith Katkin director | $91k 10,000 shares | +11% | |
| 36Weak | Syndax Pharmaceuticals Inc | Neil Gallagher President, Head of R&D | $72k 4,618 shares | -5% | |
| 37Weak | Syndax Pharmaceuticals Inc | Keith A. Goldan Chief Financial Officer | $59k 3,777 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.